| Autor: |
Yongsheng Huang, Yuntan Qiu, Linxiaoxiao Ding, Shuwei Ren, Yuanling Jiang, Jiahuan Luo, Jinghua Huang, Xinke Yin, Sha Fu, Jianli Zhao, Kaishun Hu, Jianwei Liao |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
The Journal of Pathology: Clinical Research, Vol 10, Iss 2, Pp n/a-n/a (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2056-4538 |
| DOI: |
10.1002/2056-4538.12367 |
| Popis: |
Abstract Breast cancers involving mutations in homologous recombination (HR) genes, most commonly BRCA1 and BRCA2 (BRCA1/2), respond well to PARP inhibitors and platinum‐based chemotherapy. However, except for these specific HR genes, it is not clear which other mutations contribute to homologous recombination defects (HRD). Here, we performed next‐generation sequencing of tumor tissues and matched blood samples from 119 breast cancer patients using the OncoScreen Plus panel. Genomic mutation characteristics and HRD scores were analyzed. In the HR genes, we found that BRCA1/2 and PLAB2 mutations were related to HRD. HRD was also detected in a subset of patients without germline or somatic mutations in BRCA1/2, PLAB2, or other HR‐related genes. Notably, LRP1B, NOTCH3, GATA2, and CARD11 (abbreviated as LNGC) mutations were associated with high HRD scores in breast cancer patients. Furthermore, functional experiments demonstrated that silencing CARD11 and GATA2 impairs HR repair efficiency and enhances the sensitivity of tumor cells to olaparib treatment. In summary, in the absence of mutations in the HR genes, the sensitivity of tumor cells to PARP inhibitors and platinum‐based chemotherapy may be enhanced in a subset of breast cancer patients with LNGC somatic mutations. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text